Literature DB >> 1180586

Cholecystokinin metabolism in man and dogs.

J C Thompson, H R Fender, N I Ramus, H V Villar, P L Rayford.   

Abstract

We have developed a sensitive, specific and reproducible radioimmunoassay for cholecystokinin (CCK) with which basal levels of CCK of between 400-800 pg/ml have been measured in normal man, in patients with diabetes and with duodenal ulcer disease, and in normal dogs. After a meal, circulating levels of CCK rose to 1000-1200 pg/ml in human subjects. Release of CCK was more rapid in diabetic and duodenal ulcer patients than in normal subjects, but elevated postprandial levels persisted much longer in normal subjects. Patients with the Zollinger-Ellison syndrome had elevated values of cholecystokinin which rose after a meal. Lack of correlation between elevated basal levels of gastrin and CCK in patients with the Zollinger-Ellison syndrome suggest that the hypercholecystokininemia may be absolute. The disappearance half-time of exogenous CCK was about 21/2 minutes in normal subjects as well as in diabetic and duodenal ulcer patients. Studies in dogs demonstrated no uptake of basal levels of cholecystokinin by the kidney; on infusion of exogenous CCK-33, the kidney extracted 43% of the total CCK presented and 56% of the integrated CCK. We conclude that: 1) circulating basal and postprandial levels of CCK may be measured in a reproducible fashion; 2) postprandial release of CCK is more rapid in diabetic and duodenal ulcer patients than in normal man; 3) the disappearance half-time of exogenous CCK in man and dogs is about 21/2 minutes; 4) the kidney is a major site for uptake of CCK.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1180586      PMCID: PMC1344019          DOI: 10.1097/00000658-197510000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine.

Authors:  A A Harper; H S Raper
Journal:  J Physiol       Date:  1943-06-30       Impact factor: 5.182

3.  Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome.

Authors:  J C Thompson; D D Reeder; H V Villar; H R Fender
Journal:  Surg Gynecol Obstet       Date:  1975-05

4.  A radioimmunoassay for cholecystokinin-pancreozymin.

Authors:  R F Harvey; L Dowsett; M Hartog; A E Read
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

5.  Effect of secretin on circulating gastrin.

Authors:  J C Thompson; D D Reeder; H H Bunchman; H D Becker; E N Brandt
Journal:  Ann Surg       Date:  1972-09       Impact factor: 12.969

6.  A method for producing specific antisera with small doses of immunogen.

Authors:  J Vaitukaitis; J B Robbins; E Nieschlag; G T Ross
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

7.  The isolation and chemistry of secretin and cholecystokinin.

Authors:  J E Jorpes
Journal:  Gastroenterology       Date:  1968-08       Impact factor: 22.682

8.  Comparison of effects of gastrin, cholecystokinin-pancreozymin, secretin, and glucagon on human stomach muscle in vitro.

Authors:  A J Cameron; S F Phillips; W H Summerskill
Journal:  Gastroenterology       Date:  1970-10       Impact factor: 22.682

9.  Radioimmunoassay of porcine cholecystokinin-pancreozymin.

Authors:  V L Go; R J Ryan; W H Summerskill
Journal:  J Lab Clin Med       Date:  1971-04

10.  Renal uptake and excretion of gastrin in the dog.

Authors:  B G Clendinnen; W D Davidson; D D Reeder; B M Jackson; J C Thompson
Journal:  Surg Gynecol Obstet       Date:  1971-06
View more
  12 in total

1.  Effect of selective and nonselective muscarinic blockade on cholecystokinin-induced gallbladder emptying in man.

Authors:  V Garrigues; J Ponce; C Cano; R Sopena; M Hoyos; A Del Val; J Berenguer
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

Review 2.  Biliary motility.

Authors:  P A Grace; G J Poston; R C Williamson
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

3.  Radioimmunoassay of gastrointestinal hormones.

Authors:  P L Rayford; K Hejtmancik; J C Thompson
Journal:  World J Surg       Date:  1979-08-31       Impact factor: 3.352

Review 4.  Exercise and gall bladder function.

Authors:  A Utter; F Goss
Journal:  Sports Med       Date:  1997-04       Impact factor: 11.136

5.  Effect of metiamide on basal and stimulated serum cholecystokinin levels in duodenal ulcer patients.

Authors:  R W Spence; L R Celestin; R F Harvey
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

6.  Cholecystokinin in acute alcoholic and biliary pancreatitis.

Authors:  S Räty; J Sand; E Kemppainen; S Laine; I Nordback
Journal:  Int J Pancreatol       Date:  2000-08

Review 7.  Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.

Authors:  A J Desai; M Dong; K G Harikumar; L J Miller
Journal:  Int J Obes Suppl       Date:  2016-11-16

8.  Pathogenesis and characterization of hyperglucagonemia in the uremic rat.

Authors:  D S Emmanouel; J B Jaspan; S F Kuku; A H Rubenstein; A I Katz; A H Huen
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

9.  Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy?

Authors:  M Ventrucci; C Campieri; M Di Stefano; G M Ubalducci; S Li Bassi; A Di Grazia; A Giudicissi; D Festi
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

10.  Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.

Authors:  M C Jebbink; J B Jansen; A A Masclee; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.